24TOPNEWSFinancial IntelligenceBETA中文
← Overview
Healthcare · 13.1

Pharmaceuticals

Quantified news impact based on deduplicated, quality-reviewed events in a single 200-day window.

Average net impact+24weighted per event
Average gross impact33absolute weighted average
Events24same period
Confidence81%model average
Raw intensity62before weighting
Previous period0net impact
Gross changeInsufficient base
Diffusion speed0.1 / day
Concentration5%
Direction disagreement27%
Source independence98%14 sources
IMPACT TREND

200-day effective impact

Positive 19 · Negative 3 · Mixed 2

Current periodPrevious period
TIME HORIZON

Impact duration

Immediate0%0 cumulative effective impact
Short term42%337 cumulative effective impact
Medium term51%412 cumulative effective impact
Long term7%53 cumulative effective impact
CO-IMPACT

Related industries

13.3Biotechnology14 shared events+2810.1Semiconductor Value Chain3 shared events+4313.15Pharmaceutical R&D Services3 shared events+1913.2Traditional Chinese Medicine3 shared events+191.14Batteries & Energy Storage2 shared events+408.3New Energy Vehicles2 shared events+391.11Wind & Solar Equipment2 shared events+3710.5Robotics2 shared events+34
EVENT EVIDENCE

Events ranked by effective impact

Page 3 of 3 · 24 events

Macro1
01
Macropositive

Hong Kong Q2 2026 Ad Spending Up 5% to HK$8.77 billion, World Cup Boosts June by 9%

Hong Kong's advertising spending in the second quarter of 2026 rose 5% year-on-year to HK$8.77 billion, with June surging 9% driven by the World Cup. Social media ranked first in expenditure, followed by television, mobile, search engine marketing and outdoor advertising. Among the top 10 industries, banking, credit cards and investment services grew 19% year-on-year, while insurance jumped 56% to eighth place.

Effective
+18
Intensity
40
Confidence
70%
Horizon
Short term
Industries2
01
Industriesmixed

15 Pharma Firms in 2026 Fortune 500; Eli Lilly Jumps to 224th as Tirzepatide Tops Global Drug Sales

The 2026 Fortune Global 500 lists 15 pharmaceutical companies, unchanged from 2025 but with reshuffled rankings. Eli Lilly posted the largest leap, rising 112 spots to 224th, with revenue surging 44.7% to $65.179 billion and profit soaring 94.9% to $20.64 billion. Its GLP-1 drug tirzepatide generated $36.507 billion in sales, surpassing Novo Nordisk's semaglutide ($36.1 billion) to become the world's best-selling medicine. Novo Nordisk also gained 35 places, and both companies led profit margins among pharma peers.

Effective
0
Intensity
80
Confidence
90%
Horizon
Medium term
02
Industriesmixed

China Launches 12th Batch Drug Procurement Covering 65 Varieties with New Rules

China's 12th national drug volume-based procurement (VBP) has been launched, covering 65 varieties across therapeutic areas including hypertension, diabetes, oncology, and anti-infection. New rules include a 'zero-volume winning' mechanism that uses statistical standard deviations to set anchor prices, preventing extreme low bids. A separate channel for reference-listed drugs allows qualification without volume guarantees. Reporting by brand is fully implemented, with 45,000 medical institutions submitting demand for over 500 pharmaceutical companies, averaging 15 bidders per variety and over 50 for the most competitive.

Effective
0
Intensity
60
Confidence
80%
Horizon
Short term
Companies1
01
Companiespositive

Anke Bio's Wholly-Owned Unit Suhao Yiming Gets NMPA Approval for Terlipressin Acetate API

Anke Bio's wholly-owned sub-subsidiary, Shanghai Suhao Yiming Pharmaceutical Co. , Ltd. , received on July 29 the Chemical API Marketing Application Approval Notice from China's National Medical Products Administration for terlipressin acetate. The active pharmaceutical ingredient will be used to produce terlipressin preparations, which are indicated for gastrointestinal bleeding, genitourinary bleeding, postoperative bleeding, and hepatorenal syndrome.

Effective
+12
Intensity
40
Confidence
70%
Horizon
Short term